EP3377085A4 - Peptide und verfahren zur behandlung von endometriose damit - Google Patents

Peptide und verfahren zur behandlung von endometriose damit Download PDF

Info

Publication number
EP3377085A4
EP3377085A4 EP16862963.2A EP16862963A EP3377085A4 EP 3377085 A4 EP3377085 A4 EP 3377085A4 EP 16862963 A EP16862963 A EP 16862963A EP 3377085 A4 EP3377085 A4 EP 3377085A4
Authority
EP
European Patent Office
Prior art keywords
peptides
methods
same
treating endometriosis
endometriosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16862963.2A
Other languages
English (en)
French (fr)
Other versions
EP3377085A1 (de
Inventor
Eytan R. Barnea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioIncept LLC
Original Assignee
BioIncept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/058877 external-priority patent/WO2016073513A1/en
Application filed by BioIncept LLC filed Critical BioIncept LLC
Publication of EP3377085A1 publication Critical patent/EP3377085A1/de
Publication of EP3377085A4 publication Critical patent/EP3377085A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP16862963.2A 2015-11-03 2016-11-03 Peptide und verfahren zur behandlung von endometriose damit Withdrawn EP3377085A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2015/058877 WO2016073513A1 (en) 2014-11-03 2015-11-03 Pif binding as a marker for immune dysregulation
US201662317628P 2016-04-03 2016-04-03
PCT/US2016/060319 WO2017079430A1 (en) 2015-11-03 2016-11-03 Peptides and methods of treating endometriosis using the same

Publications (2)

Publication Number Publication Date
EP3377085A1 EP3377085A1 (de) 2018-09-26
EP3377085A4 true EP3377085A4 (de) 2019-07-17

Family

ID=58663080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16862963.2A Withdrawn EP3377085A4 (de) 2015-11-03 2016-11-03 Peptide und verfahren zur behandlung von endometriose damit

Country Status (5)

Country Link
EP (1) EP3377085A4 (de)
AU (1) AU2016349358B2 (de)
CA (1) CA3004055A1 (de)
IL (1) IL259096A (de)
WO (1) WO2017079430A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2017040186A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Compositions and methods for the treatment of neurodamage
CA3071012A1 (en) * 2017-07-17 2019-01-24 Bioincept, Llc Peptides and methods of transplantation and restorative organ function
CN113845582B (zh) * 2021-10-15 2022-05-27 南京市妇幼保健院 内源性多肽在制备预防或治疗子宫内膜癌靶向药物中的应用
EP4248985A1 (de) * 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptide für die behandlung von retinitis pigmentosa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
WO2000063675A1 (en) * 1999-04-16 2000-10-26 Bioincept, Inc. Identification of a serum marker for endometriosis
US7723290B2 (en) * 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7723289B2 (en) * 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
WO2016073513A1 (en) * 2014-11-03 2016-05-12 Bioincept, Llc Pif binding as a marker for immune dysregulation
CA2903817A1 (en) * 2013-03-12 2014-10-09 Institute of Arthritis Research, LLC Immunologically active polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCO SBRACIA ET AL: "PreImplantation Factor in endometriosis: A potential role in inducing immune privilege for ectopic endometrium", PLOS ONE, vol. 12, no. 9, 13 September 2017 (2017-09-13), pages e0184399, XP055439008, DOI: 10.1371/journal.pone.0184399 *
See also references of WO2017079430A1 *

Also Published As

Publication number Publication date
IL259096A (en) 2018-06-28
AU2016349358B2 (en) 2019-12-05
EP3377085A1 (de) 2018-09-26
CA3004055A1 (en) 2017-05-11
AU2016349358A1 (en) 2018-06-14
WO2017079430A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
HK1249058A1 (zh) 用於增强靶向蛋白質降解的化合物和方法
EP3442991A4 (de) Ras-bindende peptide und verfahren zur verwendung
EP3157471A4 (de) Exoskelett und verfahren zur verwendung davon
EP3303435A4 (de) Hydrofluorolefine und verfahren zur verwendung davon
IL276515A (en) Antibodies specific to PD-L1 and methods of using them
EP3283516A4 (de) Anti-pacap-antikörper und verwendungen davon
EP3145523A4 (de) Ras-hemmerpeptide und verwendungen davon
EP3341027A4 (de) Transfektionskomplexe und verfahren zur verwendung davon
EP3303436A4 (de) Hydrofluorolefine und verfahren zur verwendung davon
HK1247091A1 (zh) 治療抗體及其用途
EP3274472A4 (de) Antimikrobielle peptide und verfahren zur verwendung davon
IL259096A (en) Peptides and methods of treating endometriosis using the same
HK1243118A1 (zh) 新型支撑劑及其使用方法
EP3215172A4 (de) Modifikationen und verwendungen von conotoxin-peptiden
EP3288379A4 (de) Peptidzusammensetzungen und verfahren zur verwendung
EP3220908A4 (de) Zusammensetzungen und verfahren zur behandlung von endometriose
ZA201901942B (en) Nnif and nnif-related peptides and related methods
EP3356418A4 (de) Anti-podocalyxin-antikörper und verfahren zur verwendung davon
EP3334730A4 (de) Pyrrolomycine und verfahren zur verwendung davon
EP3341006A4 (de) Zusammensetzungen und verfahren zur behandlung von nervenschäden
EP3313427A4 (de) Therapeutische peptide und verfahren zur verwendung davon
EP3371332A4 (de) Verfahren und materialien zur behandlung von autoimmunkrankheiten
EP3336186A4 (de) Depdc1-abgeleitetes peptid und impfstoff damit
EP3319930A4 (de) Verfahren und zusammensetzungen zur stabilisierung von proteinen
EP3341739A4 (de) Mutierte peptide und verfahren zur behandlung von subjekten damit

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038000000

Ipc: G01N0033567000

A4 Supplementary search report drawn up and despatched

Effective date: 20190614

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20190607BHEP

Ipc: C07K 7/08 20060101ALI20190607BHEP

Ipc: G01N 33/564 20060101ALI20190607BHEP

Ipc: G01N 33/567 20060101AFI20190607BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230314